Clinical Trial

Spermatogenesis Suppression

Study Description

Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men

This is a Phase IIa multicenter, double-blind, placebo-controlled study in healthy men to evaluate the spermatogenesis suppression after oral administration of Dimethandrolone Undecanoate (DMAU) alone or with Levonorgestrel (LNG) for 12 weeks versus placebo alone.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Dimethandrolone-Undecanoate

Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.

Drug - Levonorgestrel 0.03 MG

Single doses of LNG administered in 30 mcg capsules.

Drug - Placebo oral capsule

Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.

Additional Information

Official Study Title

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of Spermatogenesis Suppression After Oral Administration of Dimethandrolone Undecanote (DMAU) Alone or With Levonorgestrel (LNG) for 12 Weeks Versus Placebo Alone in Normal Men

Clinical Trial ID

NCT03455075

ParticipAid ID

9aAvpb